CN1686553A - Anti entity tumour medicinal composition - Google Patents
Anti entity tumour medicinal composition Download PDFInfo
- Publication number
- CN1686553A CN1686553A CN 200510042260 CN200510042260A CN1686553A CN 1686553 A CN1686553 A CN 1686553A CN 200510042260 CN200510042260 CN 200510042260 CN 200510042260 A CN200510042260 A CN 200510042260A CN 1686553 A CN1686553 A CN 1686553A
- Authority
- CN
- China
- Prior art keywords
- tumor
- acid
- entity
- combination
- vinorelbine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
A composite medicine for treating solid tumor by locally putting it in the tumor is composed of the active anticancer component (plant alkaloid and its symergist chosen from taxol-type anticancer medicine, antineoplastic antibiotic and antimetabolitic), and the medicinal auxiliary (biocompatible and biodegradable high-molecular polymer).
Description
(1) technical field
The present invention relates to a kind of entity-tumor-resistant medicine composition, belong to technical field of pharmaceuticals.
(2) background technology
Treatment for cancer mainly comprises methods such as operation, radiotherapy and chemotherapy.In used various chemotherapeutics, the action effect of plant alkaloid is comparatively obvious, has been widely used in multiple malignant tumor.Yet separately the DNA repair function in many tumor cells obviously increases after the appliable plant alkaloid, so effectively reduce or suppress the emphasis that DNA repair function in the tumor cell just becomes current research.
Recent findings, deactivation or suppress intracellular dna repair protein and can strengthen the sensitivity of part tumor cell to chemotherapy, referring to " 06-benzyl guanine analog is to the effect of human tumor cells to the cell toxicant sensitivity of alkylating agent " " cancer research " 51 phase 3367-3372 pages or leaves (1991) such as Doran (Dolan et al., Cancer Res., 51,3367-3372,1991)).Yet, blood vessel in the mesenchyma stroma of tumors, connective tissue, stromatin, fine micro protein and collagen protein etc. not only provide support and requisite nutrient substance for the growth of tumor cell, also influenced chemotherapeutics around tumor and infiltration and diffusion in the tumor tissues, " situation of extracellular matrix is to the influence of medicine running in the entity tumor " " cancer research " 60 phase 2497-503 page or leaf (2000) (Netti PA such as carry referring to the Buddhist nun, Cancer Res.2000,60 (9): 2497-503).Because entity tumor excessive expansion hypertrophy, the viscosity of matter was high than its normal surrounding tissue all between matter pressure, tissue elasticity pressure, fluid pressure reached therebetween, therefore, conventional chemotherapy, be difficult to tumor by local and form effective drug level, referring to " placing cisplatin adding system carmustine treatment rat brain tumor in the tumor " " surgery tumor magazine " 69 phase 76-82 pages or leaves (1998) (Kong Q et al., J Surg Oncol.1998 Oct such as Kong Qingzhongs; 69 (2): 76-82), improve the restriction that dosage is subjected to general reaction again merely.
In addition, the cancer drug therapy of low dosage not only can increase the Drug tolerance of cancerous cell, but also can promote the growth of its wettability "; referring to beam etc. " increased after the cancer therapy drug pulse screening human lung carcinoma cell Drug tolerance and external invade the profit ability and with the change of gene expression " " international journal of cancer " 111 phase 484-93 page or leaf (2004) (Liang Y; et al., Int J Cancer.2004; 111 (4): 484-93).Because the principal element of decision therapeutic effect is the drug level of tumor by local and the tumor cell sensitivity to medicine.And the blood vessel in the mesenchyma stroma of tumors, connective tissue, stromatin, fine micro protein and collagen protein etc. not only provide support and requisite nutrient substance for the growth of tumor cell, have also influenced chemotherapeutics around tumor and infiltration and diffusion in the tumor tissues.
(3) summary of the invention
The present invention is directed to the deficiencies in the prior art, a kind of entity-tumor-resistant medicine composition is provided.
Entity-tumor-resistant medicine composition of the present invention comprises anticancer effective component and pharmaceutic adjuvant, and wherein anticancer effective component is plant alkaloid and plant alkaloid synergist.Wherein, the plant alkaloid synergist is one of paclitaxel kind anti-cancer drugs thing, antitumor antibiotics or antimetabolitas or combination.
Plant alkaloid is selected from one of following or combination: vinblastine, leurosidine, the Changchun indole, the Changchun chlormethine, the oxo bridge vinblastine, vincristine (Vincristine, leurocristine), Podophyllinic Acid (mitopodozide), vincristine sulfate, vincaleucoblastine (Vinblastine), the tartaric acid F 81097, the tartaric acid leurosine, leurosine, the tartaric acid catharanthine, Hainanensine, Hainanolide, vinpocetine, vinorelbine (Vinorelbine, Vinorebine), Vinorelbine monotartrate, the two tartrates of vinorelbine, Vinorelbine tartrate, Vinmegallate (Vinmegallate), vinleurosine (Vinleurosine), vinleucinol (Vinleucinol), vinglycinate (Vinglycinate), Deacetylvincaleucoblastine 4-(N,N-dimethylglycinate) sesquisulfate, virosine, vinfosiltine (Vinfosiltine), vinformide (Vinformide), vinflunine (Vinfiunine), vinepidine (Vinepidine), vindesine (Vindesine, vindesine), vinzolidine (Vinzolidine), vintriptol (Vintriptol), vinrosidine (Vinrosidine), oxymatrine, cephalotaxin (Cephalotaxin), 3(R)-Deoxyharringtonine, homoharringtonine (Homoharringtonine), aranotin, monocrotaline (Monocrotaline), maitansine, elliptinium acetate, total alkaloid of harmaline, heart chrysanthemum lactone, Mei Dengsu, rubescensine A, pretazettine, tazettine before the hydrochloric acid, thalictrine, thalidasine, 2,3,5,6-tetramethoxyphenanthro[9,10:6',7', tylophorimidine or white cottonrose hibiscus alkali.Above plant alkaloid cancer therapy drug also comprises their salt, as, but be not limited to sulfate, phosphate, hydrochlorate, Lactobionate, acetate, aspat, nitrate, citrate, purine or pyrimidine salt, tartrate, succinate or maleate.
Above plant alkaloid serves as preferred with vincristine, vincaleucoblastine, vinorelbine or cephalotaxin.
Plant alkaloid shared ratio in compositions is decided because of concrete condition, and generally speaking, percentage by weight can be good with 1%-50% from 0.01%-99.99%, is best with 5%-30%.
Be selected from one of following or combination as the paclitaxel kind anti-cancer drugs thing (taxanes) of plant alkaloid synergist: paclitaxel (Paclitaxel, taxol, taxol), Docetaxel (Docetaxel, taxotere, docetaxel) and the derivant of paclitaxel, as, but be not limited to, 2 '-hydroxyl taxol (paclitaxel-2 '-hydroxy), 10-go the acetyl Baccatine III (10-deacetylbaccatin III, DAB), 14 beta-hydroxies-10-removes acetyl Baccatine III (14-OH-DAB), 9-dihydro-13-Baccatine III (DHB), IDN5109,10-removes acetyl taxol (10-deacetyl taxol), 7-table-taxol (7-epi-taxol), Tetraol, Baccatine III (baccatin III), Tetraol V, Semen Caesalpiniae Ramulus et folium taxi cuspidatae (Taxus brevifolia), ground hemlock (Taxus Canadensis), yew (Taxus baccata) and Chinese Ramulus et folium taxi cuspidatae (Taxus chinensis), pointed tooth Ramulus et folium taxi cuspidatae (Taxus cuspidata), cultivate Ramulus et folium taxi cuspidatae (Taxus X mediacultivars), Yunnan Ramulus et folium taxi cuspidatae Taxus yunnanensis) or Florida Ramulus et folium taxi cuspidatae (Taxus floridana).Above paclitaxel kind anti-cancer drugs thing also comprises their salt, as, but be not limited to sulfate, phosphate, hydrochlorate, Lactobionate, acetate, aspat, nitrate, citrate, purine or pyrimidine salt, succinate or maleate.
Above-mentioned paclitaxel kind anti-cancer drugs thing serves as preferred with paclitaxel, Docetaxel (docetaxel) or 2 '-hydroxyl taxol, and the content in compositions is the 1-50% percentage by weight.
Suppress by combining that RNA is synthetic to be used for the treatment of various cancers as the antitumor antibiotics of plant alkaloid synergist with DNA.
Antitumor antibiotics is selected from one of following or combination: carcinomycin, bleomycin (Bleomycin, Bleomycin A5, Pingyangmycin), (hydrochloric acid) bleomycin, zorbamycin, the piperazine bleomycin, sulphuric acid piperazine bleomycin, antibiotic 1588, bouvardin, clarithromycin (Clarithromycin), aklavine (Aclacinomycin A, aclarubicin, ACLA, aclarubicin), aklavine-B, 9-[4-(N-Methylacetamido)anilino, 9-(4-(N-Methylacetamido)anilino)-7-methyl-1H-imidazo(4,5-f)quinoline, kidamycin, acetylkitamycin (acetyl kidamycin), azotomycin (azotomycin), daunorubicin (daunorubicin, DNR, daunomycin, rubidomycin, daunorubicin, daunomycin), Diacetoxysciroenol (Diacetoxysciroenol), doxorubicin hydrochloride (doxorubicin, doxorubicin, adriamycin), triferricdoxorubicin, epirubicin (epiadriamycin) or epirubicin (Epirubicin), Valrubicin (valrubicin), pirarubicin, 7-O-methyl Nuo Jia-4 '-epirubicin (7-o-methylnogallol-4 '-epiadriamycin), diethoxy acetyl amycin, ciclamicin, mitomycin (Mitomycin), ametycin (mitomycin C), NSC-69529, actinomycin D (Dactinomycin), actinomycin C, cyclosporin A, Carzinocidin (carzinocidin), carzinophillin (carzinophylin), cardinophyllin, the tumor rhzomorph, carzinostatin (carzinostatin, carcinostain), neocarzinostain NCS (neocarzinostain), diazamycine (diazamycine), Macrocin (macrocin), macrocinomycin (macrocinomycin), dactinomycin, alanopsin, alazopeptin, the A Le lid, neothricin (neothricin, neothramycin), macromycin (macromomycin or macromycin), neothramycin A, nocardin (nocardin), nocardorubin. (nocardorubin), 2-[N-(2-amidinoethyl)carbamoyl (noformicin), nogalamycin (promise Garamycin, nogalamycin or nogaromycin), Mitochromine mitocromine B-35251 (mitochromine or mitocromine), polymyxin E (Polymyxin E), pirlimycin (Pirlimycin), dirithromycin (Dirithromycin), antramycin, oxalysine, duazomycin, Olivomycin, rufocromomycin, NSC-45384, streptozotocin, peplomycin, puromycin, sparsomycin, talisomycin, Anthrapyrazole, losoxantrone [Losoxantrone], mitoxantrone (Mitoxantrone), piroxantrone [Piroxantrone], teloxantrone [Teloxantrone], hydroxyl nitre D-glucosamine ring element, anthramycin (anthramycin, antramycin), methylanthramycin, Ai Fei ground can be peaceful, asperlin, (hydrochloric acid) Carrninomycin I, talisomycin, macromycin, O-Demethyldaunomycin, NSC-178248, chromomycin A3, chlorine assistant star (chlorozotocin), demethylrifampicin, ditrisarubicins, Hitachimycin, deoxycoformycin, puromycin, puromycin hydrochloride, rachelmycin, rebeccamycin, Sangivamycin, sarkomycin, sibiromycin, talisomycin, rice holder Zuro, selenazofurin, Antibiotic BMG-162aF2, spirogermanium hydrochloride, Spirogermanium, Spirophydantoin Mustard or stibcytostatum.
Above-mentioned antitumor antibiotics serves as preferred with bleomycin, daunomycin, aclarubicin, amycin, epirubicin, pirarubicin, Valrubicin, ametycin, actinomycin D, losoxantrone, mitoxantrone, piroxantrone, teloxantrone or chlorine assistant star.
Antimetabolitas as the plant alkaloid synergist can stop the synthetic of DNA in different links respectively, suppresses the cell division increment, and cell cycle and DNA are synthetic to play a role by influencing.
Antimetabolite is selected from one of following or combination:
Pemetrexed (Alimta), pemetrexed disodium, Rumi Qu Sai, doxifluridine (Doxifloridine, fortulon), the 5-doxifluridine, floxuridine (fluridine), propylthiouracil, fluorouracil (Fluoracil, Fluracil), the fluorobutane uracil, 5-fluorouracil (Fluorouracil, 5-FU), tegadifurum, the 5-fluoxydin, sulfomercaprine sodium, mercaptopurine (Mercaptopurine, happy disease is peaceful, 6-MP), mercapto miaow purine, Ismipur, the adenine hydrochlorate, Benin, thioguanine (thioguanine, 6-TG), sulfur crow purine, tisupurin, Hydrazinium sulfate, dianhydrogalactitol, Aziridinyl Benzoquinone, but sweet smell Luoning, isoeuxanthone, chalone, chlorine is bent phosphoric acid, clastoban, cycloleucine, look into the Chinese holly woods, methyl yellow is looked into the Chinese holly woods sourly, Bai Ruikuaer, oxipurinol, Australia Ma Lite, bromine crust acid (sodium), Brytoslatin-I, bromine urea glycosides, fluorine urea hexylamine, folic acid, methotrexate (methotrexate, MTX), 10-ethyl denitrification aminopterin (deaza-aminopterin), fluoromethotrexate, the dioxy methotrexate, 5, the 10-lonetrexol, N5-Methyltetrahydrohmofotic Acid, buthiopurin, his amide of Dinke, Guang azepine crow glycosides, carmofur (Carmofur), ftorafur (Tegafur, tegafur, FT-207), Tegafur-uracil mixt., 6-prenylindole, 6-thioinosine, UFT (Tegafur-Uracil, UFT), coralyne, N-foymylsarcolysin, ammonia (base) pterin (aminopterin), aminopterin sodium (Aminopterin Sodium), 8-azaguanine (8-azaguanine), 6-dimethylamino-8-azaadenosine, (nitro) imuran (azathioprine), uracil, 5-mercaptomethyluracil, azaserine (azaserine), Raltitrexed (Raltitrexed), nolatrexed dihydrochloride, sophoridine, formyl tetrahydrofolic acid, 5-methyltetrahydrohomofolate, Zoledronate, thunder accounts for for song, the temozolomide, bicalutamide, asparaginase (L-Asparaginase, left-handed asparagine), calcium levofolinate, calcium folinate (Calcium Levofolinate, calcium leucovorin), Quinespar, triazinate, trimetrexate, tramadol, the 5-chlorobarbituric acid, 5-diazonium uracil, piracetam, hycamtin, topotecan hydrochloride, ZD-9331, BHAC, SM108, cytosine arabinoside (cytosine arabinoside, Cytarabine (Ara-C)), ancitabine (cyclotidine, Cyclocytidine], hydroxyurea (Hydroxycarbamide, hydroxyurea), the hydroxyl guanidine, the 5-fluorouracil nucleoside, the 5-fluorouracil deoxynucleoside claims fluorouracil deoxynucleoside (floxuridine) again, glycerol Citrus chachiensis Hort. alkali, A Lei can loose, HCFU, 5 ' DFUR, TK-177, isoxazole acetic acid, aminoglutethimide (ethylbenzene amine piperidones, aminoglutethimidium, aminoglutethimide), amonafide, 5-chloro-5-deoxyarabinosylcytosine, atamestane, azacytidine (Azacitidine, 5-azacytidine, the atropic cytidine, AzGR), chloramphenalan (betamerphalan, Betamerphalan), decitabing, dexrazoxane [Dexrazoxane], crisnatol, cristatic acid, carat is sharp flat, the sharp guest of carat, galocitabine [Galocitabine], gemcitabine [Gemcitabine], ibacitabine [Ibacitabine], enocitabine [Enocltabine], ancitabine [Ancitabine], decitabine [Decitabine], flurocitabine (Flurocitabine), capecitabine (Capecitabine), enocitabine, his shore of imidazoles, the non-Shandong of Crane, the OK a karaoke club amide, carzolamide, carbazylquinone, CB-1-252, curcumin, the curcumin diketone, ketotrexate, trimetrexate, Si Poguning, deoxidation Si Poguning, naphthalene urea phosphamide, Ditercalinium Chloride, F-ara AMP-2, fluorine benzyl thiophene ketone, gamlogic acid, goserelin, nitrogen Chinese holly mountain range, Hellebrigenin, inosine dialdehyde, metoprine, mitobronitol (Dibromomannitol, Mitobronitol), mitolactol (Mitolactol), Ke is for ground, Persian, eriolangin, dopan (Chlorethylaminouracil, Dopan), Mei Luogerui, Methyl GAG, GR 30921X, mitotane, fazarabine (Fazarabine), fludarabine (fludarabine), cladribine (cladribine), pentoside (pentostatin), phenaline, benzene comes U.S. special, phosphemide, hair Buddhist nun azoles, Polyprenic Acid, Pteroylaspartic Acid, pteroyltriglutamic acid, fast rice tongue pool, riboprine, simtrazene, Schizophyllan, sodium bromebrate, Solvent Yellow 3, bent fourth sulphur ester, TEM, triaziquone, triciribine, TCN-P NSC-280594, triptolide, triptorelin, nine cloth Lip river azoles, UFT, vitamin B-17, Wei Maining, z-azepine adenosine, prick western cytidine, epipropidine [Epipropidine], the A Monuo phase, adozelesin (Adozelesin), acronine (Acronine), alanosine (Alanosine), ametantrone (Ametantrone), Anastrozole, the A Naxi army, anaxirone (Anaxirone), A Si Yin wakes up, acivicin (Acivicin), atevirdine [Atevirdine], idoxifene (idoxifene), AT-236, hold high and rather study carefully Ji, individual Lu Dabuxin, antineoplaston, antineoplastons, asaphan, Aspargus Granule, AT-346, Bai Ruikuaer (sodium), (hydrochloric acid) Orang Crush, granisetron, tropisetron, dacarbazine, ondansetron, thymosin, tramadol, imatinib mesylate, diclofenac, Thalidomide, the holder fluorine kills star, toremifene, ambroxol, lappaconitine, anti-general etc. because of, thymosin, flutamide, ethyliminum, amine benzene, neoquini oxydum, the N-methylformamide, the jail can reach azoles, NSC-56045, oxisuran, oxylycorine, paphencyl, it is fixed to moor damp Nip, the penberol, prospidine chloride, protoanemonin, good generation born of the same parents, retelliptine, Sensorad, M3, solapalmitine, solaziquonum, stibenemidine, Temozoromide, the many Shillongs of platform, thiaolivacine, bifurcation pyridine of nitre ammonia or SN-11841.
Above-mentioned antimetabolite is with Ismipur, 5-fluorouracil (5-FU), pemetrexed, pemetrexed disodium, Rumi Qu Sai, doxifluridine, floxuridine, mercaptopurine, thioguanine, methotrexate, carmofur, ftorafur, galocitabine, ibacitabine, enocitabine, ancitabine, decitabine, flurocitabine, enocitabine, his shore of imidazoles, GR 30921X, mitotane, cytosine arabinoside, hydroxyurea, the 5-fluorouracil nucleoside, capecitabine, gemcitabine, fludarabine, thunder accounts for for song, Raltitrexed, the atropic cytidine, dexrazoxane, cladribine or pentoside are preferred.
Plant alkaloid synergist shared percentage by weight in compositions is decided because of concrete condition, generally speaking, can be good with 1%-50% from 0.01%-80%, is best with 5%-30%.The weight ratio of plant alkaloid and its synergist is 1-9: 1 to 1: 1-9.
Pharmaceutic adjuvant of the present invention can be through enzyme, soda acid or tissue fluid hydrolysis or degraded.Described pharmaceutic adjuvant comprises one of following or its combination:
(1) biocompatibility polymer, comprise biodegradable or biological nondegradable polymer and composition thereof or copolymer, (2) water-soluble low-molecular chemical compound is or/and (3) are used to realize the suitable additive and the excipient of pharmaceutical dosage forms such as injection and slow releasing agent.
Above-mentioned biodegradable polymer comprises natural and/or synthetic polymer.Synthetic polymer as, but be not limited to, polyanhydrides, polyhydroxy acid, polyester (polyesters), polyamide (polyamides), polypeptide (polypeptides), polyactide (polylactides) is as polylactic acid (polylactic acid), polyactide and glycolide copolymer (as the copolymer (PLGA) of glycolic and lactic acid), poe (polyorthoesters), polyphosphazene (poiyphosphazenes), to carboxy phenyl propane (p-CPP), certain herbaceous plants with big flowers diacid (sebacic acid), liposome, Polyethylene Glycol (polyglycolide) (polymer of hydroxyacetic acid and lactic acid), carboxylic acids (carboxylic acids), fatty acid (fatty acids), phospholipid (phospholipids), nucleic acid (nucleic acids), polyamino acid (polyamino acids), aminoacid such as phenylalanine (phenylalanine), tyrosine (tyrosine), different bright (isoleucine), polynucleotide (polynucleotides); Natural polymer as, but be not limited to, protein and polysaccharide (polysaccharides) comprise hyaluronic acid (hyaluronic acid), chondroitin sulfate (chondroitin sulfate), collagen protein, gelatin, albumin etc.Wherein, preferred polymer is polyactide, Polyethylene Glycol or polyactide and glycolide copolymer (as the copolymer (PLGA) of glycolic and lactic acid).
Above-mentioned polyanhydrides can be selected for use, but is not limited to, fragrant polyanhydride, aliphatic polyanhydride; Wherein fragrant polyanhydride will be separated slower, the fusing point height, and dissolubility is low in the organic solvent, however the copolymer of fragrant polyanhydride and aliphatic polyanhydride is comparatively desirable (United States Patent (USP) 4757128) but.Representative wherein is polifeprosan (to the copolymer of carboxy phenyl propane (p-CPP) and certain herbaceous plants with big flowers diacid (SA)), and is fragrant polyanhydride to carboxy phenyl propane, and the certain herbaceous plants with big flowers diacid then is the copolymer of an aromatic diacid and a fat diacid.The copolymer of available other fragrance or aliphatic polyanhydride has a detailed description in other United States Patent (USP) that (US 4857311; 4888176; 4789724).
Above-mentioned polyhydroxy acid can be selected for use, but is not limited to, the copolymer (PLGA) of mixture, glycolic and the lactic acid of polylactic acid (PLA), polyglycolic acid (PGA), polylactic acid (PLA) and polyglycolic acid.Above polyhydroxy acid can singly select or multiselect, and when singly selecting, the molecular weight of polylactic acid (PLA) can be, but is not limited to, 5000-100, and 000, but with 10,000-50000 is preferred, with 10,000-30000 is for most preferably; The molecular weight of polyglycolic acid can be, but is not limited to, 5000-100, and 000, but with 10,000-50000 is preferred, with 10,000-20000 is for most preferably; The molecular weight of the copolymer of glycolic and lactic acid (PLGA) can be, but is not limited to, 1000-100, and 000, but with 10,000-50000 is preferred; With 10,000-20000 is for most preferably; When multiselect, compound polymer or the copolymer formed with macromolecule polymer or different macromolecule polymer serve as preferred, with the compound polymer that contains different molecular weight polylactic acid or certain herbaceous plants with big flowers diacid or copolymer for most preferably, as, but be not limited to, molecular weight is 5000 to 10000 polylactic acid with molecular weight is that 20000 to 50000 polylactic acid mixes, molecular weight is 10000 to 20000 polylactic acid with molecular weight is that 30000 to 80000 PLGA mixes, molecular weight is that 5000 to 10000 polylactic acid mixes with the certain herbaceous plants with big flowers diacid, molecular weight is that 30000 to 80000 PLGA mixes with the certain herbaceous plants with big flowers diacid.When PLA and PGA mixing, its content percentage by weight is respectively 0.1-99.9% and 99.9-0.1%.Compositions can discharge effective ingredient by the mode of direct diffusion and/or degraded.Above molecular weight peak value scope is that GPC records.
The nondegradable polymer of above-mentioned biology comprises, but be not limited to: polyethylene propylene (polyvinyl propylene), polyvinylpyrrolidone (polyvinylpyrrolidone, PVP), organosilicon polymer, ethylene vinyl acetate copolymer (Ethelene-vinyl acetate copolymer, EVAc), polyacrylonitrile (polyacrylonitriles), polyurethanes (polyurethanes), silicone (silicone) and polyphosphazene (polyphosphazenes) etc.Compositions can discharge effective ingredient by the mode of direct diffusion.
For regulating other characteristic of drug releasing rate or change entity-tumor-resistant medicine composition of the present invention, can change the composition and the proportioning of monomer component or molecular weight, interpolation or the adjusting pharmaceutic adjuvant of polymer, add the water-soluble low-molecular chemical compound, as, but be not limited to various sugar or salt etc.Wherein sugar can be, but is not limited to, xylitol, oligosaccharide and chitin etc., and wherein salt can be but is not limited to, potassium salt or sodium salt etc.
The used pharmaceutic adjuvant of entity-tumor-resistant medicine composition of the present invention can be any or multiple material in the above-mentioned pharmaceutic adjuvant, but with the high molecular weight water soluble polymer is main separation, in various high molecular polymers, with polylactic acid, certain herbaceous plants with big flowers diacid, the mixture or the copolymer that contain the macromolecule polymer of polylactic acid or certain herbaceous plants with big flowers diacid is first-selection, mixture and copolymer can be selected from, but be not limited to the mixture or the copolymer of the mixture of PLA, PLGA, PLA and PLGA, certain herbaceous plants with big flowers diacid and fragrant polyanhydride or aliphatic polyanhydride.Polylactic acid (PLA) and polyglycolic acid the blend ratio be 10/90-90/10 (weight), 25/75-75/25 (weight) preferably.The method of blend is arbitrarily.Content when glycolic and lactic acid copolymerization is respectively percentage by weight 10-90% and 90-10%.The representative of fragrance polyanhydride is to carboxy phenyl propane (p-CPP), content during to carboxy phenyl propane (p-CPP) and the copolymerization of certain herbaceous plants with big flowers diacid is respectively percentage by weight 10-60% and 20-90%, the blend weight ratio is 10-40: 50-90, preferably weight ratio 15-30: 65-85.
Pharmaceutic adjuvant has a detailed description in " pharmaceutic adjuvant complete works " (the 123rd page, Sichuan science tech publishing house published in 1993, Luo Mingsheng and Gao Tianhui chief editor).In addition, Chinese patent (application number 96115937.5; 91109723.6; 9710703.3; 01803562.0) and U.S.'s patent of invention (patent No. 5,651,986) also enumerated some pharmaceutic adjuvants.Comprise filler, solubilizing agent, absorption enhancer, film former, gellant, system (or causing) hole agent, excipient or inhibitor.Above pharmaceutic adjuvant has has multiple action, and therefore the material of the same race that has is listed in different classifications.The available holder of composition for treating solid tumor of the present invention can be any or multiple material in the above-mentioned pharmaceutic adjuvant, and not exclusively comes the technical characterictic of limit combination according to its classification or definition.
The effective ingredient of entity-tumor-resistant medicine composition can be packaged in the whole pharmaceutic adjuvant equably, also can be packaged in carrier holder center or its surface; Can effective ingredient be discharged by direct diffusion or through mode or dual mode like this that polymer is degraded.In addition, the effective ingredient of composition for treating solid tumor also can be packaged in the liposome equably, or makes microsphere with art methods.
Characteristics of the present invention are that used pharmaceutic adjuvant removes the high molecular polymerization beyond the region of objective existence, also contain above-mentioned any one or multiple other pharmaceutic adjuvant.The pharmaceutic adjuvant that adds is referred to as additive.Additive can be divided into filler, porogen, excipient, dispersant, isotonic agent, preservative agent, inhibitor, solubilizing agent, absorption enhancer, film former, gellant etc. according to its function.
Pharmaceutic adjuvant also can be liquid, as, but be not limited to Oleum sesami, suspension, distilled water, physiology towards liquid and semisolid, as (but being not limited to) fruit jelly, paste, ointment etc., above-mentioned pharmaceutic adjuvant is applicable to the compositions that contains or do not contain additive.
Entity-tumor-resistant medicine composition of the present invention can be made into multiple dosage form.As, but be not limited to injection, muddy suspension, ointment, capsule, slow releasing agent, implant, implantation slow release agent etc.; Be different shape, as, but be not limited to granular, lamellar, sphere, bulk, needle-like, bar-shaped and membranaceous.In various dosage forms, based on agent for slow releasing in the body or implant.Above-mentioned dosage form and shape are applicable to the compositions that contains or do not contain additive.
Most preferred dosage form of the present invention is the implantation slow release agent that bio-capacitivity, degradable absorb, and can make different shape because of the clinical needs of difference.The packing method of its Main Ingredients and Appearance and step in United States Patent (USP) (US5651986) have a detailed description, comprise the some kinds of methods that prepare slow releasing preparation: as, but be not limited to, (i) carrier holder powder and medicament mixed be pressed into implant then, promptly so-called mixing method; (ii) carrier holder fusing, mix solid cooled then, promptly so-called fusion method mutually with medicine to be packaged; (iii) the carrier holder is dissolved in the solvent, medicine dissolution to be packaged or be scattered in the polymer solution, evaporating solvent then, the universe is dry, promptly so-called dissolution method; (iv) spray drying method; And (v) freeze-drying etc.Wherein dissolution method can be in order to the manufacturing of microsphere, and its method is arbitrarily, and anticancer pharmaceutical composition also can be packed in the liposome.
Because entity-tumor-resistant medicine composition of the present invention can make the action effect of methods such as conventional chemotherapy, immunization therapy, high thermal therapeutical, photochemical therapy, electrotherapy, Biotherapeutics, hormone therapy, magnetic therapy, ultrasonic therapeutic, radiotherapy and gene therapy strengthen.Therefore when local slow discharges, can share, thereby its anticancer effect is further strengthened with above-mentioned non-operative treatment.
Route of administration
Entity-tumor-resistant medicine composition of the present invention can be through various administrations, as in passages through which vital energy circulates, tremulous pulse, subcutaneous, muscle, Intradermal, intracavity, the tumor, tumor week etc.Route of administration depends on multiple factor, for obtaining valid density in position, tumor place, medicine can give through other number of ways, as arterial perfusion optionally, administration in the intra-bladder instillation (intracavitary), abdominal cavity (intraperitoneal) or thoracic cavity (intrapleural) and canalis spinalis.In number of ways, with topical, as with in selective arterial, the tumor, tumor week injection or be placed as the master, with in the tumor, the form that slowly discharges of tumor week or tumor chamber serve as preferably, can plant slow-releasing pump, slow releasing capsule, slow releasing agent, implant or sustained-release implant as selecting for use.With the tremulous pulse approach is good, directly is placed as the best in the tumor body.
Dosage
The consumption of cancer therapy drug depends on several factors, as, but be not limited to gross tumor volume, patient body weight, administering mode, disease progression situation and therapeutic response.Generally speaking, the plant alkaloid synergist can be 0.01-200 milligram/kg body weight, with 1-100 milligram/kg body weight is ideal, with 5-80 milligram/kg body weight for the most desirable, plant alkaloid can be 0.01-100 milligram/kg body weight, with 1-180 milligram/kg body weight is ideal, with 5-50 milligram/kg body weight for the most desirable.
Entity-tumor-resistant medicine composition of the present invention can be used to prepare the medicine of the various entity tumors for the treatment of people, house pet and animal, comprises former or cancer or sarcoma or the carcinosarcoma that shifts originating from brain, central nervous system, kidney, liver, gallbladder, incidence, oral cavity, thyroid, skin, mucosa, body of gland, blood vessel, osseous tissue, lymph node, lungs, esophagus, stomach, mammary gland, pancreas, eyes, nasopharynx part, uterus, ovary, endometrium, cervix uteri, prostate, bladder, colon, rectum.
Also can add other medicinal ingredient in the entity-tumor-resistant medicine composition of the present invention, as, but be not limited to antibiotics, antalgica, anticoagulant medicine, hemorrhage etc.Above medicinal ingredient can singly select or multiselect, can join the compositions that contains or do not contain additive, and its content is because of specifically deciding.
Above-mentioned effective ingredient is packaged in the pharmaceutic adjuvant, then topical application.Said composition can be through various administrations, with topical, as selective arterial injection and directly injection or be placed as goodly in the tumor body, wherein are released to the best with local slow again.When used the part, composition for treating solid tumor of the present invention can directly place around former or the entity tumor that shifts or in the tumor body, also can directly place former or all or part of excision of entity tumor shifted formed intracavity afterwards.
Entity-tumor-resistant medicine composition Main Ingredients and Appearance of the present invention is a holder with the bio-capacitivity material, so do not cause foreign body reaction.Support to place in the object back degradable and absorb, so no longer operation is taken out.Discharge contained drug at tumor by local, thereby optionally improve and prolong local drug concentration, can reduce the general toxic reaction that is caused by the conventional route administration simultaneously.
The characteristics of entity-tumor-resistant medicine composition technology of preparing of the present invention are plant alkaloid and/or its synergist are packaged in the pharmaceutic adjuvant, proportionally with active ingredient and pharmaceutic adjuvant dissolving, treat that abundant mixing is dry afterwards.Be shaped immediately after to be dried and sterilize packing.
Above plant alkaloid and/or its synergist are local to be placed, not only can overcome the toxic reaction that the whole body administration brings, and has solved the tumor by local drug level and cross the low and cell sensitive question to medicine.
By following test and embodiment the technology side of composition for treating solid tumor of the present invention is further described:
The external tumor-inhibiting action of test one, plant alkaloid and synergist thereof.
Used tumor cell comprises the cerebral tumor (C6), gastric gland epithelial cancer (SA), bone tumor (BC), breast carcinoma (BA), pulmonary carcinoma (LH), papillary adenocarcinoma of thyroid (PAT), hepatocarcinoma etc.To be added in 24 hours the various tumor cells of In vitro culture by 10ug/ml concentration with plant alkaloid and synergist thereof, continue to cultivate counting cells sum after 48 hours.Its tumor growth suppresses effect and is shown in Table 1.
Table 1
| Oncocyte | ??(A) | ??(B) | ??(C) | ??(D) | ??(E) | ??(A) ??+(B) | ??(A) ??+(C) | ??(A) ??+(D) | ??(A) ??+(E) |
| ??C6 | ??64％ | ??54％ | ??64％ | ??66％ | ??69％ | ??94％ | ??94％ | ??94％ | ??94％ |
| ??SA | ??58％ | ??60％ | ??56％ | ??60％ | ??62％ | ??86％ | ??85％ | ??86％ | ??86％ |
| ??BC | ??54％ | ??64％ | ??54％ | ??54％ | ??54％ | ??94％ | ??94％ | ??84％ | ??94％ |
| ??BA | ??54％ | ??62％ | ??62％ | ??52％ | ??52％ | ??98％ | ??96％ | ??98％ | ??98％ |
| ??LH | ??50％ | ??58％ | ??62％ | ??68％ | ??66％ | ??90％ | ??90％ | ??94％ | ??92％ |
| ??PAT | ??62％ | ??54％ | ??64％ | ??66％ | ??69％ | ??94％ | ??94％ | ??90％ | ??92％ |
Annotate: (A): vincristine, plant alkaloid; (B): paclitaxel, (C): Docetaxel, (D): amycin, (E): 5-fluorouracil.(B)-(E) be the plant alkaloid synergist, plant alkaloid (vincristine) is all had notable synergistic effect (P＜0.05).
The external tumor-inhibiting action of test two, plant alkaloid and synergist thereof.
Used tumor cell is with test one.Following plant alkaloid and synergist thereof are added in 24 hours the various tumor cells of In vitro culture by 10ug/ml concentration, continue to cultivate counting cells sum after 48 hours.Its tumor growth suppresses effect and is shown in Table 2.
Table 2
| Oncocyte | ??(A) | ??(B) | ??(C) | ??(D) | ??(E) | ??(A) ??+(B) | ??(A) ??+(C) | ??(A) ??+(D) | ??(A) ??+(E) |
| ??CNS | ??68％ | ??64％ | ??66％ | ??64％ | ??60％ | ??90％ | ??92％ | ??80％ | ??94％ |
| ??C6 | ??62％ | ??64％ | ??60％ | ??64％ | ??63％ | ??96％ | ??94％ | ??86％ | ??92％ |
| ??SA | ??58％ | ??60％ | ??56％ | ??60％ | ??62％ | ??86％ | ??85％ | ??86％ | ??86％ |
| ??BC | ??54％ | ??64％ | ??54％ | ??54％ | ??54％ | ??94％ | ??94％ | ??84％ | ??94％ |
| ??BA | ??54％ | ??62％ | ??62％ | ??52％ | ??52％ | ??98％ | ??96％ | ??98％ | ??98％ |
| ??LH | ??60％ | ??58％ | ??62％ | ??68％ | ??66％ | ??90％ | ??90％ | ??94％ | ??92％ |
| ??PAT | ??54％ | ??56％ | ??66％ | ??66％ | ??69％ | ??94％ | ??92％ | ??94％ | ??92％ |
Annotate: (A): vincaleucoblastine, plant alkaloid; (B): mitoxantrone, (C): ametycin, (D): epirubicin, (E): pemetrexed.(B)-(E) be the plant alkaloid synergist, plant alkaloid is all had notable synergistic effect (P＜0.05).
The external tumor-inhibiting action of test three, plant alkaloid and synergist thereof.
Used tumor cell is with test one.Following plant alkaloid and synergist thereof are added in 24 hours the various tumor cells of In vitro culture by 10ug/ml concentration, continue to cultivate counting cells sum after 48 hours.Its tumor growth suppresses effect and is shown in Table 3.
Table 3
| Oncocyte | ??(A) | ??(B) | ??(C) | ??(D) | ??(E) | ??(A) ??+(B) | ??(A) ??+(C) | ??(A) ??+(D) | ??(A) ??+(E) |
| ??C6 | ??62％ | ??64％ | ??60％ | ??64％ | ??63％ | ??96％ | ??94％ | ??86％ | ??92％ |
| ??SA | ??58％ | ??60％ | ??56％ | ??60％ | ??62％ | ??86％ | ??85％ | ??86％ | ??86％ |
| ??BC | ??54％ | ??64％ | ??54％ | ??54％ | ??54％ | ??94％ | ??94％ | ??84％ | ??94％ |
| ??BA | ??54％ | ??62％ | ??62％ | ??52％ | ??52％ | ??98％ | ??96％ | ??98％ | ??98％ |
| ??LH | ??60％ | ??58％ | ??62％ | ??68％ | ??66％ | ??90％ | ??90％ | ??94％ | ??92％ |
| ??PAT | ??54％ | ??56％ | ??66％ | ??66％ | ??69％ | ??94％ | ??92％ | ??94％ | ??92％ |
Annotate: (A): vinorelbine, plant alkaloid; (B): bleomycin, (C): Ismipur, (D): Rumi Qu Sai, (E): methotrexate.(B)-(E) be the plant alkaloid synergist, plant alkaloid is all had notable synergistic effect (P＜0.05).
Above-mentioned experimental result shows that the plant alkaloid synergist all has the notable synergistic effect to plant alkaloid.Further test shows, other synergist that the present invention is listed, as, carmofur, ftorafur, cytosine arabinoside, gemcitabine, thunder accounts for for song, Raltitrexed, dexrazoxanes etc. are to leurosidine, the Changchun indole, the Changchun chlormethine, the oxo bridge vinblastine, Podophyllinic Acid, leurosine, the tartaric acid catharanthine, Hainanensine, Hainanolide, vinpocetine, Vinmegallate, vinleurosine, vinleucinol, vinglycinate, Deacetylvincaleucoblastine 4-(N,N-dimethylglycinate) sesquisulfate, virosine, vinfosiltine, vinformide, vinflunine, vinepidine, vindesine, vinzolidine, plant alkaloid such as vintriptol or vinrosidine all has the notable synergistic effect.Though be unexpected discovery the of the present invention, be of universal significance.
Tumor-inhibiting action in the body of test four, plant alkaloid and synergist thereof.
With the rat is subjects, with 2 * 10
5Individual tumor cell subcutaneous injection is in its hypochondrium, treats that tumor growth after 14 days is divided into it following 10 groups (seeing Table 4).First group is contrast, and the 2nd to 10 group is the treatment group.Plant alkaloid and synergist thereof dosage be 5mg/kg, its percentage by weight shared in pharmaceutical composition is 5-20%.The treatment back was measured gross tumor volume size, relatively therapeutic effect (seeing Table 4) on the 30th day.
Table 4
| Test group (n) | Suffered treatment | Gross tumor volume (cm 3) | The P value |
| ??1(6) | Contrast | ??62.5±12cm 3 | |
| ??2(6) | Vincristine | ??46±11cm 3 | ??＜0.05 |
| ??3(6) | Methotrexate | ??41±8cm 3 | ??＜0.01 |
| ??4(6) | Paclitaxel | ??34±6cm 3 | ??＜0.01 |
| ??5(6) | Docetaxel | ??38±6.4cm 3 | ??＜0.01 |
| ??6(6) | 5-fluorouracil | ??36±6.8cm 3 | ?＜0.01 |
| ??7(6) | Vincristine+methotrexate | ??22±5.6cm 3 | ?＜0.001 |
| ??8(6) | Vincristine+paclitaxel | ??18±2.8cm 3 | ?＜0.001 |
| ??9(6) | Vincristine+Docetaxel | ??14±3.8cm 3 | ?＜0.001 |
| ??10(6) | Vincristine+5-fluorouracil | ??18±2.6cm 3 | ?＜0.001 |
Above plant alkaloid synergist all has notable synergistic effect (P＜0.001) to plant alkaloid.
Tumor-inhibiting action in the body of test five, plant alkaloid and synergist thereof.
With the rat is subjects, with 2 * 10
5Individual tumor cell subcutaneous injection is in its hypochondrium, treats that tumor growth after 14 days is divided into it following 10 groups (seeing Table 5).First group is contrast, and the 2nd to 10 group is the treatment group.The dosage of plant alkaloid and synergist thereof is 5mg/kg, and its percentage by weight shared in pharmaceutical composition is 10-20%.The treatment back was measured gross tumor volume size, relatively therapeutic effect (seeing Table 5) on the 30th day.
Table 5
| Test group (n) | Suffered treatment | Gross tumor volume (cm 3) | The P value |
| ??1(6) | Contrast | ??65±12cm 3 | |
| ??2(6) | Vincaleucoblastine | ??42±10cm 3 | ?＜0.05 |
| ??3(6) | Pemetrexed | ??43±8.4cm 3 | ?＜0.01 |
| ??4(6) | Rumi Qu Sai | ??36±6.2cm 3 | ?＜0.01 |
| ??5(6) | Carmofur | ??40±6.46cm 3 | ?＜0.01 |
| ??6(6) | Ftorafur | ??34±6.8cm 3 | ?＜0.01 |
| ??7(6) | Vincaleucoblastine+pemetrexed | ??26±4.8cm 3 | ?＜0.001 |
| ??8(6) | Vincaleucoblastine+Rumi Qu Sai | ??20±3.8cm 3 | ?＜0.001 |
| ??9(6) | Vincaleucoblastine+carmofur | ??16±4.4cm 3 | ?＜0.001 |
| ??10(6) | Vincaleucoblastine+ftorafur | ??14±2.2cm 3 | ?＜0.001 |
Above plant alkaloid synergist all has notable synergistic effect (P＜0.001) to plant alkaloid.
Tumor-inhibiting action in the body of test six, plant alkaloid and synergist thereof.
With the rat is subjects, with 2 * 10
5Individual tumor cell subcutaneous injection is in its hypochondrium, treats that tumor growth after 14 days is divided into it following 10 groups (seeing Table 6).First group is contrast, and the 2nd to 10 group is the treatment group.The dosage of plant alkaloid and synergist thereof is 5mg/kg, and its percentage by weight shared in pharmaceutical composition is 5-20%.The treatment back was measured gross tumor volume size, relatively therapeutic effect (seeing Table 6) on the 30th day.
Table 6
| Test group (n) | Suffered treatment | Gross tumor volume (cm 3) | The P value |
| ??1(6) | Contrast | ??68±13cm 3 | |
| ??2(6) | Vinorelbine | ??42±8cm 3 | ?＜0.05 |
| ??3(6) | Cytosine arabinoside | ??45±8cm 3 | ?＜0.01 |
| ??4(6) | Gemcitabine | ??38±6cm 3 | ?＜0.01 |
| ??5(6) | Thunder accounts for for song | ??42±6.4cm 3 | ?＜0.01 |
| ??6(6) | Raltitrexed | ??40±6.8cm 3 | ?＜0.01 |
| ??7(6) | Vinorelbine+cytosine arabinoside | ??26±4.6cm 3 | ?＜0.001 |
| ??8(6) | Vinorelbine+gemcitabine | ??20±3.6cm 3 | ?＜0.001 |
| ??9(6) | Vinorelbine+thunder accounts for for song | ??18±4.6cm 3 | ?＜0.001 |
| ??10(6) | Vinorelbine+Raltitrexed | ??20±2.6cm 3 | ?＜0.001 |
Above plant alkaloid synergist all has notable synergistic effect (P＜0.001) to plant alkaloid.
Tumor-inhibiting action in the body of test seven, plant alkaloid and synergist thereof.
With the rat is subjects, with 2 * 10
5Individual tumor cell subcutaneous injection is in its hypochondrium, treats that tumor growth after 14 days is divided into it following 10 groups (seeing Table 7).First group is contrast, and the 2nd to 10 group is the treatment group.The dosage of plant alkaloid and synergist thereof is 5mg/kg, and its percentage by weight shared in pharmaceutical composition is 15-25%.The treatment back was measured gross tumor volume size, relatively therapeutic effect (seeing Table 7) on the 30th day.
Table 7
| Test group (n) | Suffered treatment | Gross tumor volume (cm 3) | The P value |
| ??1(6) | Contrast | ??72±14cm 3 | |
| ??2(6) | Vindesine | ??42±11cm 3 | ?＜0.05 |
| ??3(6) | Amycin | ??42±6cm 3 | ?＜0.01 |
| ??4(6) | Daunomycin | ??48±86cm 3 | ?＜0.01 |
| ??5(6) | Aclarubicin | ??40±6.4cm 3 | ?＜0.01 |
| ??6(6) | Epirubicin | ??42±6.8cm 3 | ?＜0.01 |
| ??7(6) | Vindesine+amycin | ??20±3.2cm 3 | ?＜0.001 |
| ??8(6) | Vindesine+epirubicin | ??23±3.8cm 3 | ?＜0.001 |
| ??9(6) | Vindesine+aclarubicin | ??18±4.4cm 3 | ?＜0.01 |
| ??10(6) | Vindesine+daunomycin | ??20±2.2cm 3 | ?＜0.001 |
Above plant alkaloid synergist all has notable synergistic effect (P＜0.001) to plant alkaloid.
Tumor-inhibiting action in the body of test eight, plant alkaloid and synergist thereof.
With the rat is subjects, with 2 * 10
5Individual tumor cell subcutaneous injection is in its hypochondrium, treats that tumor growth after 14 days is divided into it following 10 groups (seeing Table 8).First group is contrast, and the 2nd to 10 group is the treatment group.The dosage of plant alkaloid and synergist thereof is 5mg/kg, and its percentage by weight shared in pharmaceutical composition is 5-15%.The treatment back was measured gross tumor volume size, relatively therapeutic effect (seeing Table 8) on the 30th day.
Table 8
| Test group (n) | Suffered treatment | Gross tumor volume (cm 3) | The P value |
| ??1(6) | Contrast | ??70±13cm 3 | |
| ??2(6) | Vinrosidine | ??46±10cm 3 | ?＜0.05 |
| ??3(6) | Mitoxantrone | ??41±8cm 3 | ?＜0.01 |
| ??4(6) | Ametycin | ??34±6cm 3 | ?＜0.01 |
| ??5(6) | Valrubicin | ??38±6.4cm 3 | ?＜0.01 |
| ??6(6) | Pirarubicin | ??36±6.8cm 3 | ?＜0.01 |
| ??7(6) | Vinrosidine+mitoxantrone | ??20±4.6cm 3 | ?＜0.001 |
| ??8(6) | Vinrosidine+ametycin | ??14±3.6cm 3 | ?＜0.001 |
| ??9(6) | Vinrosidine+Valrubicin | ??12±4.6cm 3 | ?＜0.001 |
| ??10(6) | Vinrosidine+pirarubicin | ??14±2.6cm 3 | ?＜0.001 |
Above plant alkaloid synergist all has notable synergistic effect (P＜0.001) to plant alkaloid.
In a word, the plant alkaloid synergist among the present invention all has the notable synergistic effect to plant alkaloid.Therefore, the effective ingredient of entity-tumor-resistant medicine composition of the present invention is the associating of any one (or multiple) plant alkaloid synergist and any one (or multiple) plant alkaloid or packs separately.The entity-tumor-resistant medicine composition that contains above effective ingredient can be made into any dosage form or shape, but serves as preferred with agent for slow releasing (or implant) type.
The preparation method of entity-tumor-resistant medicine composition of the present invention is as follows:
1. the pharmaceutic adjuvant of weighing is put into container, it is even to add organic dissolution with solvents, and the not strict qualification of the amount of organic solvent is suitable fully to be dissolved as.
2. adding the anticancer active ingredient of weighing by above-mentioned percentage by weight shakes up again.
3. removal organic solvent.Vacuum drying or cold drying all can.
4. dried solid composite is made different shape.
5. ray sterilizing (roentgendosis is different because of volume) is standby after the packing.Also available other method sterilization.
(4) specific embodiment
Embodiment 1.
With the 80mg molecular weight is that 10000 the polyglycolic acid and the copolymer (PLGA) of hydroxyacetic acid are put into container, adds 100 milliliters of dichloromethane, behind the dissolving mixing, adds 10mg vincristine and 10mg ametycin, shakes up the dry organic solvent of removing of final vacuum again.Dried solid composite is shaped immediately, and ray sterilizing after the packing must contain the entity-tumor-resistant medicine composition of 10% vincristine and 10% ametycin, all is weight percentage.The drug release time of this entity-tumor-resistant medicine composition in external normal saline is 15-20 days, is 30-40 days at the subcutaneous drug release time of mice.
Embodiment 2.
The method step that is processed into entity-tumor-resistant medicine composition is identical with embodiment 1, but different is that contained anticancer effective component is:
(A) vinblastine of 1-50%, leurosidine, the Changchun indole, the Changchun chlormethine, the oxo bridge vinblastine, vincristine, Podophyllinic Acid, vincristine sulfate, vincaleucoblastine, the tartaric acid F 81097, the tartaric acid leurosine, leurosine, the tartaric acid catharanthine, Hainanensine, Hainanolide, vinpocetine, vinorelbine, liquor epinephrinae bitartratis ophthalmicus, the two tartrates of vinorelbine, Vinorelbine tartrate, Vinmegallate, vinleurosine, vinleucinol, vinglycinate, Deacetylvincaleucoblastine 4-(N,N-dimethylglycinate) sesquisulfate, virosine, vinfosiltine, vinformide, vinflunine, vinepidine, vindesine, vinzolidine, vintriptol, vinrosidine, oxymatrine, cephalotaxin, 3(R)-Deoxyharringtonine, homoharringtonine, aranotin, monocrotaline, maitansine, elliptinium acetate, total alkaloid of harmaline, heart chrysanthemum lactone, Mei Dengsu, rubescensine A, pretazettine, tazettine before the hydrochloric acid, thalictrine, thalidasine, 2,3,5,6-tetramethoxyphenanthro[9,10:6',7', the paclitaxel of tylophorimidine or white cottonrose hibiscus alkali and 1-50%, docetaxel, 2 '-hydroxyl taxol, 10-removes the acetyl Baccatine III, 14 beta-hydroxies-10-removes the acetyl Baccatine III, 9-sodium catchol disulfonate 3-Baccatine III, 10-removes the acetyl taxol, 7-table-taxol, Tetraol, the combination of Baccatine III or Tetraol V; Or
(B) vinblastine of 1-50%, leurosidine, the Changchun indole, the Changchun chlormethine, the oxo bridge vinblastine, vincristine, Podophyllinic Acid, vincristine sulfate, vincaleucoblastine, the tartaric acid F 81097, the tartaric acid leurosine, leurosine, the tartaric acid catharanthine, Hainanensine, Hainanolide, vinpocetine, vinorelbine, liquor epinephrinae bitartratis ophthalmicus, the two tartrates of vinorelbine, Vinorelbine tartrate, Vinmegallate, vinleurosine, vinleucinol, vinglycinate, Deacetylvincaleucoblastine 4-(N,N-dimethylglycinate) sesquisulfate, virosine, vinfosiltine, vinformide, vinflunine, vinepidine, vindesine, vinzolidine, vintriptol, vinrosidine, oxymatrine, cephalotaxin, 3(R)-Deoxyharringtonine, homoharringtonine, aranotin, monocrotaline, maitansine, elliptinium acetate, total alkaloid of harmaline, heart chrysanthemum lactone, Mei Dengsu, rubescensine A, pretazettine, tazettine before the hydrochloric acid, thalictrine, thalidasine, 2,3,5,6-tetramethoxyphenanthro[9,10:6',7', the bleomycin of tylophorimidine or white cottonrose hibiscus alkali and 1-50%, daunomycin, aclarubicin, amycin, epirubicin, pirarubicin, Valrubicin, ametycin, actinomycin D, losoxantrone, mitoxantrone, piroxantrone, the combination of teloxantrone or chlorine assistant star; Or
(C) vinblastine of 1-50%, leurosidine, the Changchun indole, the Changchun chlormethine, the oxo bridge vinblastine, vincristine, Podophyllinic Acid, vincristine sulfate, vincaleucoblastine, the tartaric acid F 81097, the tartaric acid leurosine, leurosine, the tartaric acid catharanthine, Hainanensine, Hainanolide, vinpocetine, vinorelbine, liquor epinephrinae bitartratis ophthalmicus, the two tartrates of vinorelbine, Vinorelbine tartrate, Vinmegallate, vinleurosine, vinleucinol, vinglycinate, Deacetylvincaleucoblastine 4-(N,N-dimethylglycinate) sesquisulfate, virosine, vinfosiltine, vinformide, vinflunine, vinepidine, vindesine, vinzolidine, vintriptol, vinrosidine, oxymatrine, cephalotaxin, 3(R)-Deoxyharringtonine, homoharringtonine, aranotin, monocrotaline, maitansine, elliptinium acetate, total alkaloid of harmaline, heart chrysanthemum lactone, Mei Dengsu, rubescensine A, pretazettine, tazettine before the hydrochloric acid, thalictrine, thalidasine, 2,3,5,6-tetramethoxyphenanthro[9,10:6',7', the Ismipur of tylophorimidine or white cottonrose hibiscus alkali and 1-50%, 5-fluorouracil, pemetrexed, pemetrexed disodium, Rumi Qu Sai, doxifluridine, floxuridine, mercaptopurine, thioguanine, methotrexate, carmofur, ftorafur, galocitabine, ibacitabine, enocitabine, ancitabine, decitabine, flurocitabine, enocitabine, his shore of imidazoles, GR 30921X, mitotane, cytosine arabinoside, hydroxyurea, the 5-fluorouracil nucleoside, capecitabine, gemcitabine, fludarabine, thunder accounts for for song, Raltitrexed, the atropic cytidine, dexrazoxane, the combination of cladribine and pentoside.Below all be weight percentage.
Embodiment 3.
With the 80mg molecular weight is that 20000 the polyglycolic acid and the copolymer (PLGA) of hydroxyacetic acid are put into container, adds 100 milliliters of dichloromethane, behind the dissolving mixing, adds 10mg vincaleucoblastine and 10mg amycin, shakes up the dry organic solvent of removing of final vacuum again.Dried solid composite is shaped immediately, and ray sterilizing after the packing must contain the entity-tumor-resistant medicine composition of 10% vincaleucoblastine and 10% amycin.All be weight percentage.The drug release time of this entity-tumor-resistant medicine composition in external normal saline is 15-20 days, is 30-40 days at the subcutaneous drug release time of mice.
Embodiment 4. is as described in the embodiment 3, but different is that contained anticancer effective component is:
(a) vincristine of 5-30%, vincaleucoblastine, vinpocetine, vinorelbine, Vinmegallate, vinleurosine, vinleucinol, vinglycinate, vinfosiltine, vinformide, vinflunine, vinepidine, vindesine, vinzolidine, vintriptol, the paclitaxel of vinrosidine or cephalotaxin and 5-30%, docetaxel, 2 '-hydroxyl taxol, 10-removes the acetyl Baccatine III, 14 beta-hydroxies-10-removes the acetyl Baccatine III, 9-dihydroxy-13-Baccatine III, 10-removes the acetyl taxol, 7-table-taxol, Tetraol, the combination of Baccatine III or Tetraol V; Or
(b) vincristine of 5-30%, vincaleucoblastine, vinpocetine, vinorelbine, Vinmegallate, vinleurosine, vinleucinol, vinglycinate, vinfosiltine, vinformide, vinflunine, vinepidine, vindesine, vinzolidine, vintriptol, the bleomycin of vinrosidine or cephalotaxin and 5-30%, daunomycin, aclarubicin, amycin, epirubicin, pirarubicin, Valrubicin, ametycin, actinomycin D, losoxantrone, mitoxantrone, piroxantrone, the combination of teloxantrone or chlorine assistant star; Or
(c) vincristine of 5-30%, vincaleucoblastine, vinpocetine, vinorelbine, Vinmegallate, vinleurosine, vinleucinol, vinglycinate, vinfosiltine, vinformide, vinflunine, vinepidine, vindesine, vinzolidine, vintriptol, the Ismipur of vinrosidine or cephalotaxin and 5-30%, 5-fluorouracil, pemetrexed, pemetrexed disodium, Rumi Qu Sai, doxifluridine, floxuridine, mercaptopurine, thioguanine, methotrexate, carmofur, ftorafur, galocitabine, ibacitabine, enocitabine, ancitabine, decitabine, flurocitabine, enocitabine, his shore of imidazoles, GR 30921X, mitotane, cytosine arabinoside, hydroxyurea, the 5-fluorouracil nucleoside, capecitabine, gemcitabine, fludarabine, thunder accounts for for song, Raltitrexed, the atropic cytidine, dexrazoxane, the combination of cladribine and pentoside.Below all be weight percentage.
Embodiment 5.
80mg polifeprosan (to carboxy phenyl propane: certain herbaceous plants with big flowers diacid weight ratio is 20: 80) copolymer is put into container, add 100 milliliters of dichloromethane, behind the dissolving mixing, add 10mg vinorelbine and 10mg epirubicin, shake up the dry organic solvent of removing of final vacuum again.Dried solid composite is shaped immediately, and ray sterilizing after the packing must contain the entity-tumor-resistant medicine composition of 10% vinorelbine and 10% epirubicin.All be weight percentage.The drug release time of this entity-tumor-resistant medicine composition in external normal saline is 15-20 days, is 30-40 days at the subcutaneous drug release time of mice.
Embodiment 6.
The method that is processed into entity-tumor-resistant medicine composition is identical with embodiment 5, and different is that contained anticancer effective component is:
(a) combination of the paclitaxel of the vincristine of 5-30%, vincaleucoblastine, vinpocetine or vinorelbine and 5-30%, docetaxel or 2 '-hydroxyl taxol; Or
(b) combination of the bleomycin of the vincristine of 5-30%, vincaleucoblastine, vinpocetine or vinorelbine and 5-30%, daunomycin, aclarubicin, amycin, epirubicin, pirarubicin, Valrubicin, ametycin, actinomycin D, losoxantrone, mitoxantrone, piroxantrone, teloxantrone or chlorine assistant star; Or
(c) Ismipur of the vincristine of 5-30%, vincaleucoblastine, vinpocetine or vinorelbine and 5-30%, 5-fluorouracil, pemetrexed, pemetrexed disodium, Rumi Qu Sai, methotrexate, carmofur, ftorafur, cytosine arabinoside, hydroxyurea, gemcitabine, fludarabine, thunder for bently account for, the combination of Raltitrexed, atropic cytidine, dexrazoxane or cladribine.Below all be weight percentage.
Embodiment 7.
(EVAc) puts into container with the 80mg ethylene vinyl acetate copolymer, add 100 milliliters of dichloromethane dissolving mixings after, adds 10 milligrams of vinpocetines and 10mg mitoxantrone, shake up the dry removal of final vacuum organic solvent again.Dried solid composite is shaped immediately, and ray sterilizing after the packing must contain 10% vinpocetine and 10% mitoxantrone entity-tumor-resistant medicine composition.All be weight percentage.The drug release time of this entity-tumor-resistant medicine composition in external normal saline is 15-20 days, is 30-40 days at the subcutaneous drug release time of mice.
Embodiment 8.
As described in embodiment 7, different is that contained anticancer effective component is:
(a) combination of the paclitaxel of the vincristine of 5-30%, vincaleucoblastine, vinpocetine or vinorelbine and 5-30%, docetaxel or 2 '-hydroxyl taxol; Or
(b) combination of the bleomycin of the vincristine of 5-30%, vincaleucoblastine, vinpocetine or vinorelbine and 5-30%, daunomycin, aclarubicin, amycin, epirubicin, pirarubicin, Valrubicin, ametycin, actinomycin D, losoxantrone, mitoxantrone, piroxantrone, teloxantrone or chlorine assistant star; Or
(c) Ismipur of the vincristine of 5-30%, vincaleucoblastine, vinpocetine or vinorelbine and 5-30%, 5-fluorouracil, pemetrexed, pemetrexed disodium, Rumi Qu Sai, methotrexate, carmofur, ftorafur, cytosine arabinoside, hydroxyurea, gemcitabine, fludarabine, thunder for bently account for, the combination of Raltitrexed, atropic cytidine, dexrazoxane or cladribine.Below all be weight percentage.
Embodiment 9.
As described in embodiment 1,3,5 or 7, used pharmaceutic adjuvant is respectively one of following or its combination that different is:
A) molecular weight is 5000-15000,10000-20000,20000-30000, the polylactic acid of 30000-40000 or 40000-80000 (PLA);
B) molecular weight is 5000-15000,10000-20000,20000-30000,30000-40000, the polyglycolic acid of 40000-50000 or 50000-80000 and the copolymer of hydroxyacetic acid (PLGA);
C) ethylene vinyl acetate copolymer (EVAc); Or
D) to the copolymer (polifeprosan) of carboxy phenyl propane and certain herbaceous plants with big flowers diacid, to carboxy phenyl propane: certain herbaceous plants with big flowers diacid weight ratio is 10: 90,20: 80,30: 70,40: 60,50: 50 or 60: 40;
E) xylitol, oligosaccharide, chitin, potassium salt, sodium salt, hyaluronic acid, collagen protein, gelatin or albumin.
Embodiment 10.
Be processed into the method step of entity-tumor-resistant medicine composition and embodiment as described in embodiment 1,3,5 or 7, anticancer effective component that different is is one of following:
(a) combination of 10% vincristine, vincaleucoblastine or vinorelbine and 10% 5-fluorouracil;
(b) combination of 10% vincristine, vincaleucoblastine or vinorelbine and 10% methotrexate;
(c) combination of 10% vincristine, vincaleucoblastine or vinorelbine and 10% gemcitabine;
(d) combination of 10% vincristine, vincaleucoblastine or vinorelbine and 10% pemetrexed;
(e) combination of 10% vincristine, vincaleucoblastine or vinorelbine and 10% amycin;
(f) combination of 10% vincristine, vincaleucoblastine or vinorelbine and 10% epirubicin;
(g) combination of 10% vincristine, vincaleucoblastine or vinorelbine and 10% pirarubicin;
(h) combination of 10% vincristine, vincaleucoblastine or vinorelbine and 10% ametycin;
(i) combination of 10% vincristine, vincaleucoblastine or vinorelbine and 10% mitoxantrone;
(j) combination of 10% vincristine, vincaleucoblastine or vinorelbine and 10% paclitaxel;
(k) combination of 10% vincristine, vincaleucoblastine or vinorelbine and 10% docetaxel;
(l) combination of 10% vincristine, vincaleucoblastine or vinorelbine and 2 '-hydroxyl paclitaxel of 10%.More than be weight percentage.
Embodiment 11. is composition for treating solid tumor inside and outside release characteristics relatively
Get the composition for treating solid tumor among the embodiment 10, be placed in the room temperature normal saline and soak, survey the different time release amount of medicine, calculate external accumulative total and discharge percent (%).It is subcutaneous to be put in white mice, regularly takes out and surveys medicament contg, according to the residual drug amount, calculates the interior accumulative total of body and discharges percent (%).The result shows, the different pharmaceutical release in vitro no significant difference that tries discharged the about 20%, the 14th day and discharges 88-94% in first day.Try to discharge in the different pharmaceutical body also no significant difference, discharged the about 10%, 28th day and discharge more than 98% in first day.But the inside and outside discharges notable difference is arranged, release in vitro is fast than being released in the body.Can keep one month in vivo.
Claims (11)
1. entity-tumor-resistant medicine composition, comprise anticancer effective component and pharmaceutic adjuvant, it is characterized in that anticancer effective component is plant alkaloid and plant alkaloid synergist, wherein, the plant alkaloid synergist is one of paclitaxel kind anti-cancer drugs thing, antitumor antibiotics or antimetabolitas or combination.
2. the entity-tumor-resistant medicine composition according to claim 1 is characterized in that described plant alkaloid is selected from one of following or combination:
Vinblastine, leurosidine, the Changchun indole, the Changchun chlormethine, the oxo bridge vinblastine, vincristine, Podophyllinic Acid, vincristine sulfate, vincaleucoblastine, the tartaric acid F 81097, the tartaric acid leurosine, leurosine, the tartaric acid catharanthine, Hainanensine, Hainanolide, vinpocetine, vinorelbine, liquor epinephrinae bitartratis ophthalmicus, the two tartrates of vinorelbine, Vinorelbine tartrate, Vinmegallate, vinleurosine, vinleucinol, vinglycinate, Deacetylvincaleucoblastine 4-(N,N-dimethylglycinate) sesquisulfate, virosine, vinfosiltine, vinformide, vinflunine, vinepidine, vindesine, vinzolidine, vintriptol, vinrosidine, oxymatrine, cephalotaxin, 3(R)-Deoxyharringtonine, homoharringtonine, aranotin, monocrotaline, maitansine, elliptinium acetate, total alkaloid of harmaline, heart chrysanthemum lactone, Mei Dengsu, rubescensine A, pretazettine, tazettine before the hydrochloric acid, thalictrine, thalidasine, 2,3,5,6-tetramethoxyphenanthro[9,10:6',7', tylophorimidine or white cottonrose hibiscus alkali.
3. the entity-tumor-resistant medicine composition according to claim 1 is characterized in that described paclitaxel kind anti-cancer drugs thing one of is selected from or combination:
Paclitaxel, docetaxel, 2 '-hydroxyl taxol, 10-go acetyl Baccatine III, 14 beta-hydroxies-10-to go acetyl Baccatine III, 9-sodium catchol disulfonate 3-Baccatine III, 10-to remove acetyl taxol, 7-table-taxol, Tetraol, Baccatine III or Tetraol V.
4. the entity-tumor-resistant medicine composition according to claim 1 is characterized in that described antitumor antibiotics one of is selected from or combination: bleomycin, daunomycin, aclarubicin, amycin, epirubicin, pirarubicin, Valrubicin, ametycin, actinomycin D, losoxantrone, mitoxantrone, piroxantrone, teloxantrone or chlorine assistant star.
5. the entity-tumor-resistant medicine composition according to claim 1 is characterized in that described antimetabolitas one of is selected from or combination:
Ismipur, 5-fluorouracil, pemetrexed, pemetrexed disodium, Rumi Qu Sai, doxifluridine, floxuridine, mercaptopurine, thioguanine, methotrexate, carmofur, ftorafur, galocitabine, ibacitabine, enocitabine, ancitabine, decitabine, flurocitabine, enocitabine, his shore of imidazoles, GR 30921X, mitotane, cytosine arabinoside, hydroxyurea, the 5-fluorouracil nucleoside, capecitabine, gemcitabine, fludarabine, thunder accounts for for song, Raltitrexed, the atropic cytidine, dexrazoxane, cladribine or pentoside.
6. the entity-tumor-resistant medicine composition according to claim 1 is characterized in that the effective ingredient of this anti-cancer composition is:
(a) combination of the paclitaxel of the vincristine of 5-30%, vincaleucoblastine, vinpocetine or vinorelbine and 5-30%, docetaxel or 2 '-hydroxyl taxol; Or
(b) combination of the bleomycin of the vincristine of 5-30%, vincaleucoblastine, vinpocetine or vinorelbine and 5-30%, daunomycin, aclarubicin, amycin, epirubicin, pirarubicin, Valrubicin, ametycin, actinomycin D, losoxantrone, mitoxantrone, piroxantrone, teloxantrone or chlorine assistant star; Or
(c) Ismipur of the vincristine of 5-30%, vincaleucoblastine, vinpocetine or vinorelbine and 5-30%, 5-fluorouracil, pemetrexed, pemetrexed disodium, Rumi Qu Sai, methotrexate, carmofur, ftorafur, cytosine arabinoside, hydroxyurea, gemcitabine, fludarabine, thunder for bently account for, the combination of Raltitrexed, atropic cytidine, dexrazoxane or cladribine; Below all be weight percentage.
7. the entity-tumor-resistant medicine composition according to claim 1, it is characterized in that, described pharmaceutic adjuvant is selected from the macromolecule polymer of bio-capacitivity, the mixture or the copolymer of macromolecule polymer, specifically is selected from the copolymer of polylactic acid, polyglycolic acid and hydroxyacetic acid, to one of carboxy phenyl propane and certain herbaceous plants with big flowers diacid copolymer, ethylene vinyl acetate copolymer or its combination.
8. the entity-tumor-resistant medicine composition according to claim 1 is characterized in that pharmaceutic adjuvant is selected from one of following or its combination:
A) molecular weight is 5000-15000,10000-20000,20000-30000, the polylactic acid of 30000-40000 or 40000-80000;
B) molecular weight is 5000-15000,10000-20000,20000-30000,30000-40000, the polyglycolic acid of 40000-50000 or 50000-80000 and the copolymer of hydroxyacetic acid;
C) ethylene vinyl acetate copolymer; Or
D) to the copolymer of carboxy phenyl propane and certain herbaceous plants with big flowers diacid, to carboxy phenyl propane: certain herbaceous plants with big flowers diacid weight ratio is 10: 90,20: 80,30: 70,40: 60,50: 50 or 60: 40;
E) xylitol, oligosaccharide, chitin, potassium salt, sodium salt, hyaluronic acid, collagen protein, gelatin or from albumen.
9. the anticancer pharmaceutical composition according to claim 1 is characterized in that this anti-cancer composition is mainly suspension, slow releasing agent, implant or implantation slow release agent.
10. the application of the described entity-tumor-resistant medicine composition of claim 1 is used to prepare the medicine that treatment originates from cancer, sarcoma or the carcinosarcoma of people and animal brain, central nervous system, kidney, liver, gallbladder, incidence, oral cavity, thyroid, skin, mucosa, body of gland, blood vessel, osseous tissue, lymph node, lungs, esophagus, stomach, mammary gland, pancreas, eyes, nasopharynx part, uterus, ovary, endometrium, cervix uteri, prostate, bladder, colon or rectum former or secondary.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100422606A CN100500218C (en) | 2005-04-06 | 2005-04-06 | Anti tumour medicinal composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100422606A CN100500218C (en) | 2005-04-06 | 2005-04-06 | Anti tumour medicinal composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1686553A true CN1686553A (en) | 2005-10-26 |
| CN100500218C CN100500218C (en) | 2009-06-17 |
Family
ID=35304595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100422606A Expired - Fee Related CN100500218C (en) | 2005-04-06 | 2005-04-06 | Anti tumour medicinal composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100500218C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104146999A (en) * | 2014-08-08 | 2014-11-19 | 深圳大学 | Oridonin and docetaxel toxicity reducing and efficacy enhancing antitumor drug composition and application thereof |
| CN104758279A (en) * | 2014-01-02 | 2015-07-08 | 中国药科大学 | Preparation methods and pharmaceutical applications of compound compositions capable of reversing taxol resistance |
-
2005
- 2005-04-06 CN CNB2005100422606A patent/CN100500218C/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104758279A (en) * | 2014-01-02 | 2015-07-08 | 中国药科大学 | Preparation methods and pharmaceutical applications of compound compositions capable of reversing taxol resistance |
| CN104146999A (en) * | 2014-08-08 | 2014-11-19 | 深圳大学 | Oridonin and docetaxel toxicity reducing and efficacy enhancing antitumor drug composition and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100500218C (en) | 2009-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100500219C (en) | Anti tumour medicinal composition containing platinum compound | |
| CN100350974C (en) | Anticarcinogen composition | |
| CN1861055A (en) | Composite slow-releasing anticarcinogen injection contg. platinum compounds | |
| CN1846672A (en) | Anticancer medicine composition containing antimetabolite | |
| CN100374160C (en) | Anti-cancer medicine composition containing antimetabolite | |
| CN1824313A (en) | Slow release microsphere containing hormone kind anti cancer medicine and its application | |
| CN100500218C (en) | Anti tumour medicinal composition | |
| CN100500212C (en) | Anti entity tumour medicinal composition | |
| CN100431606C (en) | Anti-cancer medicine composition | |
| CN1923173B (en) | Anti-cancer drugs slow release agent comprising anticancer antibiotics and synergist thereof | |
| CN1857723A (en) | Slow released anticancer medicine preparation with both amrubicin and its synergist | |
| CN100500216C (en) | Anti entity tumour medicinal composition containing dichloro ethamine kind drug | |
| CN100453118C (en) | Antientity tumour medicinal composition containing topoenzyme inhibitor | |
| CN100431608C (en) | Anti entity tumour medicinal composition containing tetrazine kind compound | |
| CN1846670A (en) | Anticancer implant | |
| CN100340297C (en) | Anticarcinogenic internal implant agent | |
| CN1923284A (en) | Anti-cancer drug slow release injection and uses thereof | |
| CN101244272B (en) | Anti-solid tumors pharmaceutical combination containing topological enzyme inhibitor | |
| CN101066452A (en) | Solid tumor treating medicine composition containing | |
| CN101066451A (en) | Solid tumor treating medicine composition containing dicloethamine | |
| CN1973820A (en) | Anticancer composition containing Sirolimus and its application | |
| CN1733304A (en) | Anticancer medicine composition containing blood vessel inhibitor | |
| CN101327185A (en) | Anticancer sustained-release implantation agent | |
| CN101244271A (en) | Anti-solid tumors pharmaceutical combination containing topological enzyme inhibitor | |
| CN1850041A (en) | Anticancer medicine slow-release preparation containing platinum compound and its synergist |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP02 | Change in the address of a patent holder |
Address after: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 1750 Co-patentee after: Kong Qingzhong Patentee after: Shandong Lanjin Pharmaceuticals Co., Ltd. Address before: 250100 No. 69, building 7, Pioneer Park, Huayang Road, Ji'nan hi tech Development Zone, Shandong, -802 Co-patentee before: Kong Qingzhong Patentee before: Shandong Lanjin Pharmaceuticals Co., Ltd. |
|
| ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: KONG QINGZHONG Owner name: SHANDONG ENDUO BIOPHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: SHANDONG LANJIN BIOENGINEERING CO., LTD. Effective date: 20110421 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 250101 NO. 1750, TIANCHEN ROAD, HIGH-TECH. ZONE, JI NAN CITY, SHANDONG PROVINCE TO: 250101 201, NO. 1750, TIANCHEN ROAD, HIGH-TECH. ZONE, JI NAN CITY, SHANDONG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20110421 Address after: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 1750 201 Patentee after: Shandong many biological pharmaceutical Co., Ltd. Address before: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 1750 Co-patentee before: Kong Qingzhong Patentee before: Shandong Lanjin Pharmaceuticals Co., Ltd. |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090617 Termination date: 20120406 |